IGC Opens Marketing and Research Hub in Colombia
IGC Pharma, Inc. (IGC)
NASDAQ:AMEX Investor Relations:
igcinc.us/investor-center/overview
Company Research
Source: Business Wire
Targets Expansion of Products to Latin America BETHESDA, Md.--(BUSINESS WIRE)--India Globalization Capital, Inc. (NYSE: IGC) announced today that it has opened a marketing and research office in Colombia, South America. Hamsa Biochem SAS, a new beneficially owned subsidiary of IGC, will focus on marketing and research initiatives to advance Hyalolex™, Holi Hemp™, and other products in Latin America and among the greater Hispanic community in the United States, in compliance with applicable law and regulations. Hyalolex™, which is currently available in more than 40 dispensaries in Puerto Rico, is based on a formulation described in a patent filing acquired from the University of South Florida (USF) in 2017, with pre-clinical research that indicates that micro-doses of cannabis, in combination with other natural compounds, may be beneficial to Alzheimer’s cell lines and to memory in transgenic mice.As described in our September 19, 2019 press release, we are advancing our research i
Show less
Read more
Impact Snapshot
Event Time:
IGC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IGC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IGC alerts
High impacting IGC Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
IGC
News
- IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s PipelineAccesswire
- IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss TherapiesAccesswire
- IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1Accesswire
- IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE ChallengeAccesswire
- IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer's TreatmentBusiness Wire
IGC
Analyst Actions
- 9/3/24 - Ascendiant Capital
IGC
Sec Filings
- 11/12/24 - Form 10-Q
- 9/27/24 - Form 8-K
- 9/27/24 - Form 4
- IGC's page on the SEC website